Current management options in metastatic renal cell cancer

Abstract

Renal cancer accounts for 2.4% of all cancers. Localised disease accounts for the majority of renal cancers (70-75%), however 20-25% of these ultimately develop distant metastasis. The median overall survival of un treated metastatic disease is 5 months with 1-year survival of only 29%. The management of metastatic renal cell cancers traditionally relied on systemic immunotherapy with attendant high morbidity but after the year 2005 the use of effective targeted therapy with tolerable side effect profile has improved the survival from 10.2 months in the cytokine era to 17.7 months. This article reviews the past, present and future options in the management of metastatic renal cancer.

Dimensions

Altmetric

PlumX Metrics

Downloads

Download data is not yet available.
Published
2017-06-14
Info
Issue
Section
Reviews
Keywords:
Renal cancer, metastatic disease, targeted therapy, immunotherapy.
Statistics
  • Abstract views: 1353

  • PDF: 718
  • HTML: 157
How to Cite
Gangadaran, S. G. D. (2017). Current management options in metastatic renal cell cancer. Oncology Reviews, 11(2). https://doi.org/10.4081/oncol.2017.339